We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Effects of Limicol on LDL-cholesterol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01354327
Recruitment Status : Completed
First Posted : May 16, 2011
Last Update Posted : May 16, 2011
Information provided by:

Study Description
Brief Summary:
The principal objective of this study is to investigate the effects of a novel food supplement (Limicol) on LDL-cholesterol levels in healthy subjects with moderate hypercholesterolemia.

Condition or disease Intervention/treatment
Hypercholesteremia Dietary Supplement: Limicol Dietary Supplement: Placebo

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 47 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Study of the Effects of Limicol (a Food Supplement) on LDL-cholesterol in Moderate Hypercholesterolemia Subjects
Study Start Date : December 2008
Primary Completion Date : May 2011
Study Completion Date : May 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Limicol Dietary Supplement: Limicol
3 tablets / day during 4 months
Placebo Comparator: Placebo Dietary Supplement: Placebo
3 tablets / day during 4 months

Outcome Measures

Primary Outcome Measures :
  1. Change from Baseline in blood LDL-cholesterol levels at 4 months [ Time Frame: 4 months ]

Secondary Outcome Measures :
  1. Change from Baseline in blood Vit. C, Vit. E, polyphenols and MDA levels at 4 months [ Time Frame: 4 months ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • About 18 to 55 years (inclusive)
  • Subject has a stable weight for at least three months before the start of the study
  • Subject able and willing to comply with the protocol and agreeing to give their consent in writing
  • Subject affiliated with a social security scheme
  • Subject willing to be included in the national register of volunteers who lend themselves to biomedical research
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01354327

Marseille, France, 13005
Sponsors and Collaborators
Lescuyer Laboratory
CIC Hôpital de la Conception - Marseille
Aix Marseille Université
Study Director: Sébastien Peltier, PhD Lescuyer Laboratory
More Information

Responsible Party: Peltier, Lescuyer Laboratory
ClinicalTrials.gov Identifier: NCT01354327     History of Changes
Other Study ID Numbers: 2008-A01169-46
First Posted: May 16, 2011    Key Record Dates
Last Update Posted: May 16, 2011
Last Verified: May 2011

Keywords provided by Lescuyer Laboratory:
Delivery of Health Care
Coronary artery disease
Red yeast rice
Plants extract
Cholesterol excess

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases